Overview Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury Status: Recruiting Trial end date: 2024-04-01 Target enrollment: Participant gender: Summary The purpose of this study is to assess the safety, tolerability and pharmacokinetics of ALMB-0166 in patients with acute spinal cord injury. Phase: Phase 1 Details Lead Sponsor: AlaMab Therapeutics (Shanghai) Inc.